James Geraghty
Président chez PIERIS PHARMACEUTICALS, INC.
Fortune : 1 M $ au 31/05/2024
Profil
James Arthur Geraghty is currently the Chairman at Catalent JNP, Inc., Pieris Pharmaceuticals, Inc., Orchard Therapeutics (Europe) Ltd., OMass Therapeutics Ltd., Bio Ventures for Global Health, Therapeutic Human Polyclonals, Inc., Voyager Therapeutics, Inc., CANbridge Life Sciences Ltd., Fulcrum Therapeutics, Inc., and CANbridge Pharmaceuticals Inc. He previously served as the Chairman, President & Chief Executive Officer at rEVO Biologics, Inc. and the Chairman at Catalent JNP, Inc. from 2015 to 2018.
He was also the Chairman at Orchard Therapeutics Plc from 2018 to 2024.
Additionally, he held positions as a Director at Idera Pharmaceuticals, Inc., ImmuneXcite, Inc., and bluebird bio, Inc. He was a Director at Aceragen, Inc. from 2013 to 2023 and served as the Senior Vice President at Third Rock Ventures LLC from 2013 to 2016.
Prior to that, he was the Senior Vice President-International Development at Genzyme Corp.
from 2007 to 2011 and the President at Genzyme Europe BV from 1998 to 2000.
He also worked as the Senior VP-Strategy & Business Development at Sanofi SA from 2012 to 2013.
Mr. Geraghty holds a graduate degree from the University of Pennsylvania, an undergraduate degree from Georgetown University, and a graduate degree from Yale Law School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 90 714 ( 0,15% ) | 712 105 $ | 31/05/2024 | |
| 05/06/2024 | 76 588 ( 0,14% ) | 643 339 $ | 31/05/2024 | |
| 17/04/2024 | 250 ( 0,02% ) | 2 538 $ | 31/05/2024 |
Postes actifs de James Geraghty
| Sociétés | Poste | Début |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2014 |
| FULCRUM THERAPEUTICS, INC. | Directeur/Membre du Conseil | 19/07/2016 |
| PIERIS PHARMACEUTICALS, INC. | Président | 21/11/2017 |
| JUNIPER PHARMACEUTICALS INC | Président | - |
| CANBRIDGE PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 18/07/2018 |
CANbridge Life Sciences Ltd.
 CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Directeur/Membre du Conseil | 01/05/2017 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Président | 29/06/2018 |
| Bio Ventures for Global Health | Directeur/Membre du Conseil | 12/10/2010 |
Therapeutic Human Polyclonals, Inc.
 Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Therapeutic Human Polyclonals, Inc. develops human antibody therapeutics. Its technology will enable the generation of monoclonal and polyclonal antibody therapeutics. The company is headquartered in Mountain View, CA. | Directeur/Membre du Conseil | - |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de James Geraghty
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de James Geraghty
| University of Pennsylvania | Graduate Degree |
| Georgetown University | Undergraduate Degree |
| Yale Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| ACERAGEN, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
Catalent JNP, Inc.
 Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
| Caremark International, Inc. | Health Services |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
ImmuneXcite, Inc.
 ImmuneXcite, Inc. Pharmaceuticals: MajorHealth Technology ImmuneXcite, Inc. operates as a biopharmaceutical company which develops monoclonal antibodies for cancer. The firm provides nivel immuno-incology technology platform, which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types. The company was Ifat Rubin-Bejerano, Gerald R. Fink and Yaniv Bejerano and is headquartered in Waltham, MA. | Health Technology |
| Bio Ventures for Global Health | |
Therapeutic Human Polyclonals, Inc.
Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Therapeutic Human Polyclonals, Inc. develops human antibody therapeutics. Its technology will enable the generation of monoclonal and polyclonal antibody therapeutics. The company is headquartered in Mountain View, CA. | Health Technology |
Joslin Diabetes Center, Inc.
 Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA. | Health Technology |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Health Technology |
| Sanofi SA | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Commercial Services |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
